Actuate Therapeutics Inc
Research Actuate Therapeutics Inc (ACTU) on Bullrun: market cap USD 14.65M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerACTU
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 14.65M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 4.87M
- Free cash flow-USD 4.41M
Valuation Snapshot
latest market cap is USD 14.65M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 22.23M | -USD 19.21M | n/a | -1.06 | USD 13.16M | n/a | USD 7.92M |
| FY2024 | USD 0 | -USD 27.29M | -USD 21.84M | n/a | -3.26 | USD 8.64M | USD 6.90M | USD 104.19K |
| FY2023 | USD 0 | -USD 24.74M | -USD 21.63M | n/a | -17.24 | USD 2.96M | n/a | -USD 99.63M |
| FY2022 | USD 0 | -USD 20.16M | -USD 17.79M | n/a | -1.34 | USD 20.45M | n/a | -USD 75.31M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 14.65M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 142.26M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 155.47M | n/a | n/a | n/a |
About Actuate Therapeutics Inc
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Actuate Therapeutics Inc's market cap?
Actuate Therapeutics Inc's market capitalization is USD 14.65M.
What does Actuate Therapeutics Inc do?
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc.